HC Surgical Specialists Limited, an investment holding company, provides medical services primarily in Singapore. The company provides endoscopic procedures, including gastroscopies and colonoscopies; and general surgery services with a focus on colorectal procedures in a network of clinics. It also offers treatment services for other conditions, such as haemorrhoids, anal fissure, hernia, anal abscess, cholecystitis, anal fistula, appendicitis, colorectal cancer, lipomas, cysts, and gastric cancer, vein laser vascular, laparoscopy, and other general and specialized medical services. In addition, the company provides orthopedic services comprising joint pain, sports injuries, osteoarthritis, rotator cuff tears, trigger finger, wounds/lumps, bumps, joint replacement, arthroscopic surgery, knee osteotomy, realignment surgery, endoscopic spine surgery, disc replacements, spinal decompression, fractures, and orthobiologic injections. Further, it provides home care services, which include medical, nursing, physiotherapy, speech therapy, occupational therapy, and ambulance services; health screening, management of acute and chronic conditions, and pre-employment check-up; public health preparedness clinic scheme, swab and send home program, community health assist scheme, and COVID-19 swab test services. Additionally, the company offers diagnostic tests that comprise blood tests, X-Rays, ultrasound, CT scans, and MRIs. HC Surgical Specialists Limited was incorporated in 2015 and is based in Singapore.
Metrics to compare | HCSU | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHCSUPeersSector | |
---|---|---|---|---|
P/E Ratio | 11.8x | 5.5x | −0.4x | |
PEG Ratio | −0.80 | 0.01 | 0.00 | |
Price/Book | 2.6x | 0.9x | 2.6x | |
Price / LTM Sales | 2.3x | 1.7x | 2.9x | |
Upside (Analyst Target) | - | 11.0% | 51.7% | |
Fair Value Upside | Unlock | 10.3% | 9.5% | Unlock |